AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 271 min read$IQV

IQVIA 3Q 2026: Revenue $4.43B, Net income $352M, EPS $2.1— 10-Q Summary

IQVIA Holdings reported Q3 2026 revenue of $4.43B, up 8% YoY, with net income of $352M (6% growth) and EPS of $2.1 (8.8% growth). Growth was driven by Commercial Solutions and Research & Development Solutions. The company expects $9.4B of backlog to convert within 12 months.

Original reporting
tradingview.com
Published Oct 27, 2026, 9:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 9:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
IQVIA 3Q 2026: Revenue $4.43B, Net income $352M, EPS $2.1— 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$IQVNeutralMed
01

Why it matters

The Q3 2026 earnings numbers set the tone for the company's outlook and may affect analyst forecasts.

02

Market read

First‑report earnings data for a mid‑cap health‑care services firm; relevant for sector investors.

03

What to watch

Backlog conversion timeline and segment re‑structuring may influence future performance.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

IQVIA is a leading provider of data, technology and services to the life‑sciences industry.

Company-level read

Ticker impact

$IQVNeutralHigh confidence
Context

IQVIA Holdings reported its Q3 2026 revenue, net income and EPS in a 10‑Q filing.

Expected impact

possible pressure if results fall short of consensus; upside if they beat expectations

Evidence & confidence

First‑report of quarterly numbers; market will price any surprise.

Market effects

Sector

Results provide insight into the health of the health‑data and contract research services sector.

Regional

U.S. healthcare services segment may be affected.

Global

Limited to investors tracking IQVIA and comparable global CROs.

Counterpoint

What could challenge this read

If the market expects higher growth, the modest 8% revenue increase could be seen as a miss.

Key entities

  • company
    IQVIA Holdings Inc.

    Provider of health‑care data and analytics.

Read at source← All news

StoryIQVIA reports Q3 2026 beat and lifts full‑year revenue and EPS outlook

Also covered by

5 outlets

Related articles

OCT 28
$IQVMedAI 8/10

IQVIA Holdings Inc (IQV) (Q3 2026) Earnings Call Highlights: Record Bookings, Raised

IQVIA Holdings Inc. reported Q3 2026 earnings with record bookings and raised guidance. Revenue was $4.428B, up 8% YoY, and adjusted EBITDA rose 8.7%. Challenges include FX headwinds and R&D backlog adjustments. Management highlighted AI adoption and strong biotech demand. Full-year 2026 guidance was increased, with revenue expected between $17.35B-$17.5B. No 2027 guidance was provided.

finance.yahoo.com2 min
OCT 27
$IQVHighAI 8/10

What IQVIA (IQV) Said on Its Q3 Earnings Call

IQVIA reported Q3 revenue growth of 6.9% to $1.79B, with organic growth at 4%. AI adoption contributed to commercial and clinical momentum, with 415 AI agents deployed. The company raised its 2026 outlook, expecting revenue of $17.35B-$17.50B and adjusted EPS of $12.90-$13.00. Cash flow from operations was $825M, with free cash flow at $667M.

finance.yahoo.com2 min
OCT 27
$IQVHighAI 9/10

IQVIA (IQV) Q3 2026 Earnings Call Transcript

IQVIA reported Q3 2026 revenue of $4.43B, up 8%, with organic growth at 6%. Adjusted EBITDA grew 8.7% to $1.03B, and adjusted EPS rose 11.3% to $3.34. R&D solutions revenue increased 8.7%, and commercial solutions revenue grew 6.9%. The company raised full-year revenue guidance to $17.35B-$17.5B. AI deployments and emerging biopharma funding growth were highlighted.

fool.com2 min
OCT 27
$IQVHighAI 8/10

IQVIA Holdings Inc. Q3 2026 Earnings Call Summary

IQVIA Holdings Inc. reported Q3 2026 organic revenue growth of 6%, driven by clinical segment momentum and AI integration. The Emerging Biopharma segment saw record demand with $90B funding YTD. Full-year guidance was raised, with AI expected to support future margin expansion. Management highlighted competitive advantages through AI and strategic partnerships. Q4 interest expense is projected at $210M. A $2.1B backlog scrub was conducted to improve visibility.

finance.yahoo.com3 min